Biochemics Inc., announced that the company has received a U.S. patent for several wound care treatments. The patent covers treatments for varicose ulcers, or wounds that are difficult to treat as a result of cancer, diabetes and other inflammatory diseases.
The company, which develops methods for delivering drugs through the skin, said in a statement that U.S. Patent No. 8,343,486, named “Methods and Compositions for Topical Treatment of Medical Conditions Including Wounds and Inflammation,” covers formulations combining the retinoid Vitamin A and blood vessel dilators methyl nicotinate and arginine. Could this type of product also increase patient compliance?
The patent approval is half the battle, moving forward, what type of strategy needs to me implemented next to ensure this product is a success once it hits the market?
Talks between discovery and delivery are extremely important, and strategic innovation is key. So how do you identify patentable ways to distinguish your product and to work with R&D, BD and commercial teams to maximize the value of your products? At the 17th annual Drug Delivery Partnerships, Denise Hickey, Senior Director of IP Strategy, ABBOTT LABORATORIES, leads our session: Strategic Innovation – Pro-Active IP Creation for Competitive Advantage. To learn more about the event, download the agenda.
As a reader of the Drug Delivery Partnerships Internationalblog, you get a 15% discount off the standard rate when using code XP1878BLOG to register.
No comments:
Post a Comment